A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer

被引:43
作者
Zhao, Jian Guo [2 ]
Qiu, Feng [1 ]
Xiong, Jian Ping [1 ]
Zhang, Ling [1 ]
Xiang, Xiao Jun [1 ]
Yu, Feng [1 ]
Yan, Jun [1 ]
Zhan, Zhen Yu [1 ]
Feng, Miao [1 ]
机构
[1] Nanchang Univ, Affiliated Hosp 1, Dept Oncol, Nanchang 330006, Peoples R China
[2] Shaoxing Peoples Hosp, Dept Oncol, Shaoxing, Peoples R China
关键词
5-fluorouracil; advanced gastric cancer; chemotherapy; elderly; leucovorin; oxaliplatin; ADVANCED COLORECTAL-CANCER; S-1 PLUS CISPLATIN; FOLINIC ACID; INFUSIONAL FLUOROURACIL; WEEKLY OXALIPLATIN; BIWEEKLY OXALIPLATIN; TRIAL; 5-FLUOROURACIL; LEUCOVORIN; COMBINATION;
D O I
10.1097/CAD.0b013e328324bbc1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to evaluate the efficacy and safety of biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX regimen) in elderly patients with advanced gastric cancer (AGC). Forty-six eligible patients older than 65 years with previously untreated AGC oxaliplatin 85 mg/m(2) intravenously over a 2-h period on day 1, together with leucovorin 400 mg/m(2) over 2 h, followed by a 46-h infusion of 5-fluorouracil 2600 mg/m(2) every 2 weeks. All patients were evaluable for efficacy and toxicity. A median of seven cycles (range 1-12) was administered. The overall response rate was 45.6% [95% confidence interval (CI): 31-61%] with two complete responses, 19 partial responses, 15 stable diseases, and 10 progressions. Median time to progression was 6.2 months (95% CI: 4.6-Z8) and median overall survival was 9.8 months (95% CI: 8.2-11.4). Toxicity was fairly mild. Grade 3 toxicities included neutropenia (8.7%), nausea (4.3%), vomiting (4.3%), diarrhea (2.2%); and grade 4 toxicities occurred in none of the patients. Grades 1-2 peripheral neuropathy was reported in 43.5% of patients. The modified FOLFOX regimen is active, well tolerated as first-line chemotherapy for elderly patients aged above 65 years with AGC. Anti-Cancer Drugs 20:281-286 (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins.
引用
收藏
页码:281 / 286
页数:6
相关论文
共 34 条
  • [1] Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma
    Ajani, JA
    Lec, FC
    Singh, DA
    Haller, DG
    Lenz, HJ
    Benson, AB
    Yanagilhara, R
    Phan, AT
    Yao, JC
    Strumberg, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (04) : 663 - 667
  • [2] Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin:: A study of the arbeitsgemeinschaft internistische onkologie
    Al-Batran, Salah-Eddin
    Hartmann, Joerg Thomas
    Probst, Stephan
    Schmalenberg, Harald
    Hollerbach, Stephan
    Hofheinz, Ralf
    Rethwisch, Volker
    Seipelt, Gernot
    Homann, Nils
    Wilhelm, Gerhard
    Schuch, Gunter
    Stoehlmacher, Jan
    Derigs, Hans Guenter
    Hegewisch-Becker, Susanna
    Grossmann, Johannes
    Pauligk, Claudia
    Atmaca, Akin
    Bokemeyer, Carsten
    Knuth, Alexander
    Jaeger, Elke
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) : 1435 - 1442
  • [3] Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer
    Al-Batran, SE
    Atmaca, A
    Hegewisch-Becker, S
    Jaeger, D
    Hahnfeld, S
    Rummel, MJ
    Seipelt, G
    Rost, A
    Knuth, JOA
    Jaeger, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (04) : 658 - 663
  • [4] Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC)
    Cavanna, Luigi
    Artioli, Fabrizio
    Codignola, Claudio
    Lazzaro, Antonio
    Rizzi, Anna
    Gamboni, Alessandro
    Rota, Luigina
    Rodino, Carmelina
    Boni, Fabrizio
    Iop, Aldo
    Zaniboni, Alberto
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (04): : 371 - 375
  • [5] Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer
    Chao, Y
    Yeh, KH
    Chang, CJ
    Chen, LT
    Chao, TY
    Wu, MF
    Chang, CS
    Chang, JY
    Chung, CY
    Kao, WY
    Hsieh, RK
    Cheng, AL
    [J]. BRITISH JOURNAL OF CANCER, 2004, 91 (03) : 453 - 458
  • [6] Capecitabine and oxaliplatin for advanced esophagogastric cancer
    Cunningham, David
    Starling, Naureen
    Rao, Sheela
    Iveson, Timothy
    Nicolson, Marianne
    Coxon, Fareeda
    Middleton, Gary
    Daniel, Francis
    Oates, Jacqueline
    Norman, Andrew Richard
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (01) : 36 - 46
  • [7] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
    de Gramont, A
    Figer, A
    Seymour, M
    Homerin, M
    Hmissi, A
    Cassidy, J
    Boni, C
    Cortes-Funes, H
    Cervantes, A
    Freyer, G
    Papamichael, D
    Le Bail, N
    Louvet, C
    Hendler, D
    de Braud, F
    Wilson, C
    Morvan, F
    Bonetti, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) : 2938 - 2947
  • [8] A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients
    De Vita, F
    Orditura, M
    Matano, E
    Bianco, R
    Carlomagno, C
    Infusino, S
    Damiano, V
    Simeone, E
    Diadema, MR
    Lieto, E
    Castellano, P
    Pepe, S
    De Placido, S
    Galizia, G
    Di Martino, N
    Ciardiello, F
    Catalano, G
    Bianco, AR
    [J]. BRITISH JOURNAL OF CANCER, 2005, 92 (09) : 1644 - 1649
  • [9] Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study
    deGramont, A
    Basset, JF
    Milan, C
    Rougier, P
    Bouche, O
    Etienne, PL
    Morvan, F
    Louvet, C
    Guillot, C
    Francois, E
    Bedenne, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) : 808 - 815
  • [10] Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin - Results from Intergroup Trial N09741
    Delaunoit, T
    Goldberg, RM
    Sargent, DJ
    Morton, RF
    Fuchs, CS
    Findlay, BP
    Thomas, SP
    Salim, M
    Schaefer, PL
    Stella, PJ
    Green, E
    Mailliard, JA
    [J]. CANCER, 2004, 101 (10) : 2170 - 2176